

Influenza A(H3N2) egg-derived candidate vaccine viruses for development and production of vaccines for use in the 2019 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. National or regional control authorities¹ approve the composition and formulation of vaccines used in each country.

27 September 2018 (last updated 15 November 2018)*

Candidate vaccine viruses (antigenically like A/Switzerland/8060/2017)

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Switzerland/8060/2017	Wild type virus			FCI, UK NIBSC, UK
	NIB-112	reassortant	NIBSC	NIBSC, UK
A/Brisbane/1/2018	Wild type virus			CDC, USA VIDRL, Australia
	X-311	Classical	NYMC	CDC, USA NYMC, USA
A/Brisbane/192/2017	Wild type virus			VIDRL, Australia
	IVR-187	Classical	Seqirus	CDC, USA FCI, UK NIBSC, UK NIID, Japan VIDRL, Australia
A/Rhode Island/01/2018	Wild type virus			VIDRL, Australia
	IVR-188	Classical	Seqirus	CDC, USA FCI, UK NIBSC, UK NIID, Japan VIDRL, Australia

**new candidate vaccine virus is shown in blue*

Institutes contact details for candidate vaccine virus orders/information:

CBER: fda.gov/cber
CDC: xxu@cdc.gov (Subject: CVV request)
CCDC: whocc-china@cnic.org.cn
FCI: whocc@crick.ac.uk
NIBSC: standards@nibsc.org or enquiries@nibsc.org
NIID: flu-vaccine@nih.go.jp
VIDRL: whoflu@influenzacentre.org
NYMC: doris_bucher@nymc.edu

¹ http://www.who.int/immunization_standards/national_regulatory_authorities%20offices/en/

Reference antigens (freeze-dried) – To be updated

Parent virus	Starting materials		Ref Ag Lot number	Unitage (µgHA/ml)	Available from
	Candidate vaccine virus	Egg or cell			

Sheep Antisera – To be updated

Purified HA from		Order Lot number	Available from
Parent virus	Egg or cell		

The above-listed potency testing reagents are developed with support from manufacturers, and calibrated by the WHO Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS).

ERLs contact details for reagents orders/information:

NIBSC: standards@nibsc.org or enquiries@nibsc.org

NIID: flu-vaccine@nih.go.jp

TGA: influenza.reagents@health.gov.au

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/en/

For general enquiries, please contact gisrs-whohq@who.int